KALA BIO(KALA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KALA KALA BIO

Pre-Mkt 01-13 05:37:58 EST

0.6400

+0.0085

+1.35%

High0.6400	Low0.6114	Vol501.55K
Open0.6200	D1 Closing0.6315	Amplitude4.53%
Mkt Cap17.82M	Tradable Cap14.88M	Total Shares27.85M
T/O312.87K	T/O Rate2.16%	Tradable Shares23.25M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KALA","market":"US","secType":"STK","nameCN":"KALA BIO","latestPrice":0.64,"timestamp":1768251600000,"preClose":0.6315,"halted":0,"volume":501553,"delay":0,"floatShares":23247700,"shares":27849699,"eps":-5.825375,"marketStatus":"Pre-Mkt","change":0.0085,"latestTime":"01-13 05:37:58 EST","open":0.62,"high":0.64,"low":0.6114,"amount":312866.30379030004,"amplitude":0.045289,"askPrice":0.64,"askSize":120,"bidPrice":0.5648,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.825375,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1768314600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1500523200000,"exchange":"NASDAQ","adjPreClose":0.64,"postHourTrading":{"tag":"盘后","latestPrice":0.62,"preClose":0.64,"latestTime":"19:48 EST","volume":13165,"amount":8185.98078,"timestamp":1768265280570},"volumeRatio":0.09130166029683731,"impliedVol":0.9132,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/KALA","defaultTab":"news","newsList":[{"id":"2602731356","title":"KALA BIO Inc - on Jan 8, Enters Agreement With H.c. Wainwright - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2602731356","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602731356?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:36","pubTimestamp":1767908192,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90OO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","KALA"],"gpt_icon":0},{"id":"2602313198","title":"KALA BIO Launches At-the-Market Equity Offering Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2602313198","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602313198?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:32","pubTimestamp":1767907973,"startTime":"0","endTime":"0","summary":"The latest update is out from KALA BIO ( ($KALA) ). On January 8, 2026, KALA BIO, Inc. entered into an at-the-market equity offering agreement with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kala-bio-launches-at-the-market-equity-offering-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kala-bio-launches-at-the-market-equity-offering-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KALA","BK4215","BIO","BK4585","EQR","LU1169590202.USD","LU1169589451.USD","BK4588","BK4007","BK4121"],"gpt_icon":0},{"id":"2601858334","title":"BRIEF-Kala Bio Settles Approximately $10.6 Million Of Debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2601858334","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601858334?lang=en_us&edition=fundamental","pubTime":"2026-01-06 06:16","pubTimestamp":1767651368,"startTime":"0","endTime":"0","summary":"BRIEF-Kala Bio Settles Approximately $10.6 Million Of DebtKALA BIO Inc KALA.O:KALA BIO SETTLES APPROXIMATELY $10.6 MILLION OF DEBTSource text: ID:nGNX68cgWvFurther company coverage: KALA.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA7T2MFV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","KALA","BK4139"],"gpt_icon":0},{"id":"2601837310","title":"Kala Bio Settles $10.6 Million Debt with Oxford Finance","url":"https://stock-news.laohu8.com/highlight/detail?id=2601837310","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601837310?lang=en_us&edition=fundamental","pubTime":"2026-01-06 05:10","pubTimestamp":1767647417,"startTime":"0","endTime":"0","summary":"Kala Bio Inc. has announced the successful settlement of its debt obligations with Oxford Finance, LLC. By making a $2 million payment, the company has fully satisfied and discharged approximately $10.6 million in debt as of December 26, 2025. This resolution eliminates a significant financial overhang, enhancing the company’s strategic flexibility and strengthening its stockholders' equity. The settlement follows a previously disclosed agreement related to events of default under a prior loan arrangement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kala Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL5bJvSQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","BK4139","LU2095319765.USD","BK4007","IE00BGHQF748.EUR","BK4588","NDAQ","KALA","SG9999014039.USD","SG9999014005.SGD","BK4585","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014021.USD"],"gpt_icon":0},{"id":"2601837393","title":"KALA BIO Settles Approximately $10.6 Million of Debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2601837393","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601837393?lang=en_us&edition=fundamental","pubTime":"2026-01-06 05:10","pubTimestamp":1767647405,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA7T2MFV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","KALA","BK4139"],"gpt_icon":0},{"id":"2600093824","title":"KALA BIO Inc - Pays $2 Mln to Oxford Finance Llc as Part of Settlement Agreement, Settles All Obligations - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2600093824","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600093824?lang=en_us&edition=fundamental","pubTime":"2026-01-03 05:20","pubTimestamp":1767388841,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nFWN3Y30CL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KALA","BK4139","BK4007"],"gpt_icon":0},{"id":"2600839093","title":"Kala Bio Inc. Settles $10.6 Million Debt with $2 Million Payment to Oxford Finance","url":"https://stock-news.laohu8.com/highlight/detail?id=2600839093","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600839093?lang=en_us&edition=fundamental","pubTime":"2026-01-03 05:16","pubTimestamp":1767388565,"startTime":"0","endTime":"0","summary":"Kala Bio Inc. has announced that it has paid $2 million to Oxford Finance, LLC, settling all obligations under a previous loan agreement and a related settlement agreement. With this payment, Kala Bio has resolved and released an aggregate liability of approximately $10.6 million owed to Oxford.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kala Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL3Dzlzp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KALA","BK4007"],"gpt_icon":0},{"id":"2595717287","title":"Kala Bio Inc. Announces Date for 2025 Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2595717287","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595717287?lang=en_us&edition=fundamental","pubTime":"2025-12-31 05:13","pubTimestamp":1767129237,"startTime":"0","endTime":"0","summary":"Kala Bio Inc. has announced that its 2025 annual meeting of stockholders will be held virtually on January 30, 2026. During the meeting, stockholders will consider and vote on various matters, including the Oxford Settlement and Voting Agreement, delinquent Section 16 reports, and other related items. Proposals related to stockholder submissions for the 2026 annual meeting and householding of annual meeting materials will also be addressed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kala Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 30, 2025, and is solely responsi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL2pxpV7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","KALA"],"gpt_icon":0},{"id":"2593423587","title":"Why Did Indaptus Therapeutics Surge 64% In After-Hours Trading?","url":"https://stock-news.laohu8.com/highlight/detail?id=2593423587","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593423587?lang=en_us&edition=fundamental","pubTime":"2025-12-24 11:12","pubTimestamp":1766545920,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics surged 64.65% in after-hours trading following a major insider investment and board appointment.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/23/Stock-Market-Analysis--Notebooks--Laptop.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/23/Stock-Market-Analysis--Notebooks--Laptop.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/12/49578047/why-did-indaptus-therapeutics-surge-64-in-after-hours-trading","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/12/49578047/why-did-indaptus-therapeutics-surge-64-in-after-hours-trading","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4007","RSI","LENZ","BK4139","BK4150","KALA","INDP","BK4539"],"gpt_icon":0},{"id":"2589881278","title":"KALA BIO Raises $10 Million From Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2589881278","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589881278?lang=en_us&edition=fundamental","pubTime":"2025-12-06 03:56","pubTimestamp":1764964616,"startTime":"0","endTime":"0","summary":"KALA BIO  said Friday it has closed its registered direct offering of 10 million shares at $1.00 per share, raising about $10 million.Investors could also buy pre-funded warrants in lieu, the company said.KALA BIO said it plans to use the net proceeds to repay debt and for general corporate purposes.Shares of KALA BIO fell over 5% in recent trading.Price: 0.91, Change: -0.05, Percent Change: -5.29","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1169589451.USD","BK4139","BK4588","LU1169590202.USD","KALA","BK4585","BK4007","BIO","BK4121"],"gpt_icon":1},{"id":"2588835314","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:45 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2588835314","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588835314?lang=en_us&edition=fundamental","pubTime":"2025-12-04 23:45","pubTimestamp":1764863138,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:45 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nAQN2LC3U7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","KALA","BK4139"],"gpt_icon":0},{"id":"2588835397","title":"KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2588835397","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588835397?lang=en_us&edition=fundamental","pubTime":"2025-12-04 23:45","pubTimestamp":1764863114,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA3BHXGB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","KALA"],"gpt_icon":0},{"id":"2588835393","title":"KALA BIO Inc - Purchase Price Set at $1.00 per Share in Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2588835393","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588835393?lang=en_us&edition=fundamental","pubTime":"2025-12-04 23:45","pubTimestamp":1764863114,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA3BHXGB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","KALA"],"gpt_icon":0},{"id":"2588283536","title":"Press Release: KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2588283536","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588283536?lang=en_us&edition=fundamental","pubTime":"2025-12-04 23:45","pubTimestamp":1764863100,"startTime":"0","endTime":"0","summary":"ARLINGTON, Mass., Dec. 04, 2025  -- KALA BIO, Inc.  , today announced that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 shares of its common stock , at a purchase price of $1.00 per share  in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about December 5, 2025, subject to the satisfaction of customary closing conditions.KALA is a clinical-stage biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies for rare and severe diseases of the eye. KALA's biologics-based investigational therapies utilize KALA's proprietary mesenchymal stem cell secretome  platform. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors. KPI-012 received Orphan Drug and Fast Track designations from ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","KALA","BK4007","LU1169590202.USD","BK4139","BIO","BK4121","BK4588","NQmain","BK4585"],"gpt_icon":0},{"id":"2588089900","title":"Why Did KALA BIO Shares Jump Over 22% After Hours?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588089900","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588089900?lang=en_us&edition=fundamental","pubTime":"2025-12-04 13:20","pubTimestamp":1764825600,"startTime":"0","endTime":"0","summary":"KALA BIO shares jumped over 22% after Oxford Finance acquired a 16.5% stake, amid recent leadership changes and continued year-to-date losses.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/04/Stock-Market-Analysis--Notebooks--Laptop.jpeg?optimize=medium&dpr=2&auto=webp&width=120","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/04/Stock-Market-Analysis--Notebooks--Laptop.jpeg?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/12/49201364/why-did-kala-bio-shares-jump-over-22-after-hours","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/12/49201364/why-did-kala-bio-shares-jump-over-22-after-hours","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4121","LU1169590202.USD","KALA","BK4588","BK4585","BIO","LU1169589451.USD","BK4139","BK4007"],"gpt_icon":0},{"id":"2588022991","title":"Kala Bio Inc. Files Initial Beneficial Ownership Statement Naming Oxford Finance LLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2588022991","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588022991?lang=en_us&edition=fundamental","pubTime":"2025-12-04 06:01","pubTimestamp":1764799294,"startTime":"0","endTime":"0","summary":"Kala Bio Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission, naming Oxford Finance LLC as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kala Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL25WPdp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","KALA"],"gpt_icon":0},{"id":"2588377769","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2588377769","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588377769?lang=en_us&edition=fundamental","pubTime":"2025-12-02 02:32","pubTimestamp":1764613968,"startTime":"0","endTime":"0","summary":"Q32 Bio's  shares doubled amid heavy trading after the company said Monday it sold alopecia areata drug candidate ADX-097 to Akebia Therapeutics .More than 157.3 million shares of Q32 Bio traded intraday compared with a daily average of about 223,000.Kala Bio  said Monday it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the company's non-voting convertible preferred stock.Effective immediately, Lazar has been appointed Kala's chief executive officer and chairman. Former CEO Todd Bazemore continues to serve on the board.Shares surged 58% as intraday trading volume catapulted to over 147.5 million from a daily average of about 1.7 million.Belite Bio  said Monday its phase 3 trial of Tinlarebant to treat Stargardt disease type 1 met its primary efficacy endpoint.Shares advanced 8.4% as intraday trading volume climbed to more than 611,000 from a daily average of about 90,000.Price: 4.40, Change: +2.21, Percent Change: +","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QTTB","BLTE","AKBA","KALA","BK4007","BK4139"],"gpt_icon":0},{"id":"2588724793","title":"KALA BIO Inc: Continuing to Evaluate and Redevelop Co's Product Candidates While Actively Exploring Strategic Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724793","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724793?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA9Q9SXS:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","KALA","BK4139"],"gpt_icon":0},{"id":"2588724244","title":"KALA BIO Inc - David E. Lazar Appointed as Kala's CEO and Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724244","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724244?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA9Q9SXS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","KALA","BK4139"],"gpt_icon":0},{"id":"2588347722","title":"KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar","url":"https://stock-news.laohu8.com/highlight/detail?id=2588347722","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588347722?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590400,"startTime":"0","endTime":"0","summary":"Investment to support the continued evaluation and redevelopment of KALA’s product candidates and patent portfolio, and provide working capital and funding for a potential future strategic transaction","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196847/0/en/KALA-BIO-Enters-Into-6-Million-Securities-Purchase-Agreement-with-Investor-David-E-Lazar.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","BK4007","LU1169589451.USD","BK4585","KALA","BIO","BK4121","BK4588","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kalarx.com","stockEarnings":[{"period":"1week","weight":0.039},{"period":"1month","weight":-0.0521},{"period":"3month","weight":-0.5762},{"period":"6month","weight":-0.8926},{"period":"1year","weight":-0.906},{"period":"ytd","weight":0.1513}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.035616},{"month":2,"riseRate":0.25,"avgChangeRate":-0.068238},{"month":3,"riseRate":0.625,"avgChangeRate":0.271513},{"month":4,"riseRate":0.375,"avgChangeRate":-0.095725},{"month":5,"riseRate":0.25,"avgChangeRate":-0.117576},{"month":6,"riseRate":0.5,"avgChangeRate":0.007868},{"month":7,"riseRate":0.375,"avgChangeRate":-0.025178},{"month":8,"riseRate":0.444444,"avgChangeRate":0.043537},{"month":9,"riseRate":0,"avgChangeRate":-0.257871},{"month":10,"riseRate":0.111111,"avgChangeRate":-0.21893},{"month":11,"riseRate":0.555556,"avgChangeRate":0.039437},{"month":12,"riseRate":0.333333,"avgChangeRate":0.569832}],"exchange":"NASDAQ","name":"KALA BIO","nameEN":"KALA BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"KALA BIO(KALA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest KALA BIO(KALA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"KALA BIO,KALA,KALA BIO股票,KALA BIO股票老虎,KALA BIO股票老虎国际,KALA BIO行情,KALA BIO股票行情,KALA BIO股价,KALA BIO股市,KALA BIO股票价格,KALA BIO股票交易,KALA BIO股票购买,KALA BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"KALA BIO(KALA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest KALA BIO(KALA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}